Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this document? Why not share!

Like this? Share it with your network

Share

stvincents.ie/dynamic/File/...

on

  • 1,439 views

 

Statistics

Views

Total Views
1,439
Views on SlideShare
1,439
Embed Views
0

Actions

Likes
0
Downloads
21
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

stvincents.ie/dynamic/File/... Document Transcript

  • 1. Review document for investigation and management of cognitive impairment and dementiaDefinitionMild cognitive impairment (MCI) is defined as cognitive decline greater than expected for an individual’s age andeducation level that does not interfere notably with activities of daily living (ADLs). Not all patients with MCI progress todementia, but more than 50% will.Dementia is a clinical diagnosis made when acquired cognitive deficits in more than one area of cognition interfere withADLs and represent a decline from a previously higher level of functioning.Types of dementiaThe common dementia syndromes are tabulated below. This document focuses on dementia in general, with attentiongiven to Alzheimers and vascular dementia. Type Recommended diagnostic criteria Sensitivity/specificity Alzheimers disease NINDS/ADRDA criteria Sensitivity 83%, Specificity 48% (DAT) (McKhann 1984) (Knopman 2001) Vascular dementia NINDS-AIREN criteria (Roman 1993) Sensitivity 50%, Specificity 85% (VaD) (Gold 2002) Dementia with Lewy- International Consensus criteria for DLB Sensitivity 50% Specificity low body (DLB) (McKeith 1996) (Litvan 2003, McKeith 2005) Frontotemporal Lund-Manchester criteria (Neary 1998), NINDS Neither validated against autopsy dementia (FTD) criteria for FTD (McKhann 2001)It can be difficult to differentiate between the different types of dementia clinically. In practice, mixed dementia iscommon. Dementia related to alcohol excess should be kept in mind although there are no widely accepted standardizeddiagnostic or neuropathological criteria. More rare forms of dementia include Creutzfeldt-Jakob disease, primary non-fluent aphasia and dementia due to neurosyphilis.Disease historical perspectiveIn 1901, Dr. Aloysius Alzheimer, a German psychiatrist and neuropathologist first described a case of presenile dementiain a 51-year-old woman in a German asylum. Five years later, he gave the first description of the disease associationwith amyloid plaques and neurofibrillary tangles on post-mortem brain tissue.Hachinski et al in 1974 described multi-infarct dementia, a clinical syndrome related to multiple small vessel infarcts inthe brain.Disease burden on our societyThere are currently an estimated 40,000 people in Ireland with dementia. Approximately 90% of these are over the ageof 65. In 2008, there will be approximately 4,000 new Irish dementia cases. Dementia also affects the lives of nearly50,000 people in Ireland who are involved in caring for someone with dementia.Worldwide the number of dementia sufferers is estimated at 29.8 million. (Alzheimers Society website)SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 1/13
  • 2. Health EconomicsIn 2006, the cost of dementia in Ireland was estimated at €400m. Less than 10% of this cost is attributed to communitycare. However family carers provide 57% of the value of informal care in the community without receiving financialremuneration. This undeclared hidden cost should be included in all estimates of disease burden.In 2005, the cost of dementia worldwide was estimated to be US$315.4 billion, of which US$105 billion (37%) was forinformal care (Alzheimers Society Ireland website)Future disease trendsIreland’s demography is changing and as an increased proportion of the population lives beyond their seventh decade,this will also be reflected in an increased prevalence of neurodegenerative disease in general and in the dementiasyndromes in particular. Estimates suggest a prevalence of 104,000 cases by 2037. This reflects an increase of 300%while population expansion as a whole is expected to be in the region of 40%.Worldwide, it is estimated that the number of patients with dementia will double every 20 years to 81.1 million by 2040.(Alzheimers Society Ireland website)Aetiology and Risk FactorsNon-modifiable risk factors • Age - The risk of developing dementia increases with age. It is unclear whether age is a risk factor in its own right or reflects the increasing time during which other risk factors may exert their influence. DAT prevalence in one European study of community dwelling adults was 0.6% in those aged 65-69 rising to 22% in those aged 90-years and over (Lobo 2000). • Gender - Prevalence studies describe higher rates of dementia in women than men, especially for DAT (Rocca 1991). In part, this approximate difference in prevalence of 2:1 between women and men is due to women generally living longer. Rates for VaD are higher in men, though women tend to catch up at older ages. • Family History and Genotype - A person with a positive family history of dementia may be at increased risk of developing dementia although the odds ratio is not well documented. When both parents have a clinical diagnosis of DAT, dementia risk in offspring is 31% at age over 60 and 41% at age over 70 (Jayadev 2008). The Apolipoprotein E (ApoE) ὲ4 allele located on Chromosome 19 has been identified as a risk factor for development of late onset DAT and reduces the age at which one could expect to develop the condition (Strittmatter 1993). However the effect is not equal across all racial groups. Possession of ApoE ὲ4 alone is not causative of DAT but modulates the age of onset and likelihood of the disease-becoming manifest under the influence of other aetiological factors. Several autosomal dominant forms of young-onset Alzheimers disease have been described including mutations in the amyloid precursor protein, presenilin-1 and presenilin-2 genes. Such cases are rare and characteristically patients have an age of onset of below 55 years. The risk of developing DAT is significantly higher in patients with Downs syndrome. In one North American study, DAT prevalence in institutionalized Downs syndrome patients was 55% in patients aged 50-59 and 75% in those aged 60-years and above, reflecting both an earlier age of disease onset and higher disease prevalence (Lai 1989). Familial autosomal dominant inheritance has also been shown in frontotemporal dementia. Other rare forms of inheritable dementia include cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) and Huntingtons disease.SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 2/13
  • 3. Modifiable risk factors • Cardiovascular risk factors - Cardiovascular risk factors including smoking, hypertension, diabetes mellitus and hyperlipidaemia are independent risk factors for development of VaD. They promote atherosclerosis, which is associated with development of all dementia types. One cross-sectional study found all indicators of atherosclerosis (vessel wall thickness, plaques of the carotid arteries, and the ratio of ankle-to-brachial systolic blood pressure) to be associated with all dementias, with odds ratios ranging from 1.3 to 1.9. (Hofman 1997). It is recommended that established cardiovascular risk factors be treated to reduce the risk of developing dementia and to reduce the possibility of progression of mild cognitive impairment to dementia. • Alcohol - Excessive alcohol consumption is an established risk factor for dementia. It is difficult to quantify or define the threshold of excessive alcohol consumption. Saunders described a five-fold risk of developing a psychiatric disorder including depression and dementia after the age of 65 in men with a history of five years or more of heavy alcohol consumption at any stage of life (Saunders 1991). Epidemiological cross-sectional and longitudinal prospective studies suggest a protective effect of moderate alcohol consumption (1-3 drinks per day) in unspecified dementia and DAT. Peters’ systematic review and meta-analyses of alcohol and dementia studies suggests that low to moderate alcohol consumption may reduce risk for DAT by 32% (Peters 2008) when compared with abstinence or heavy consumption (greater than three drinks per day). Methodological study weaknesses include a lack of standardization of alcohol volume measurement. Optimal consumption amounts were more than two drinks per week up to three drinks/250-500 ml per day. No evidence supports the protective effect of one type of alcoholic drink over any another. However, these associative studies should not be a basis on which to advise consumption of alcohol as a protective measure against dementia (Letenneur 2004). • Education and mental stimulation - There is some evidence that a low education level is associated with subsequent development of dementia (Valenzuela 2005). Interpretation of whether this represents a true increased risk, or reflects an alteration of the threshold at which dementia becomes apparent, is uncertain. Several studies describe a decreased rate of subsequent DAT development in subjects participating in common cognitively demanding leisure activities such as reading, playing board games and playing musical instruments (Wilson 2002, Verghese 2003). However, these findings are also compatible with the ‘cerebral reserve’ hypothesis, whereby those of higher ability, who are consequently more likely to engage in mentally stimulating activities, are also at decreased risk of subsequently developing dementia. Whilst there are many reasons to encourage engagement in such activities, further studies to assess possible protective effects of cognitive activities on risk of dementia are needed. Exercise – Limited evidence describes a protective effect of exercise on DAT development. Physical activity in mid-life (defined as lasting 20–30 minutes causing breathlessness and sweating) at least twice weekly has been associated with a 50% reduction in risk of developing dementia and DAT (Rovio 2005).Features in history and examinationDetectionPatients may self refer with subjective memory complaints. These should be taken seriously as they have been shown tobe predictive of dementia. These symptoms are however also associated with depression and anxiety disorders.Family members and friends, the general practitioner, nursing or social care staff may be the first to recognise changesin cognition, emotion or capabilities that signify possible early dementia. The collateral history of cognitive impairmentand its impact on patient function is crucial in establishing the diagnosis.A third route to recognition is through revelatory moments, for example, when the sudden incapacity of a carer revealsthe dementia processes in the patient. Patients in such instances often present as crisis admissions through theemergency services.SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 3/13
  • 4. HistoryA detailed history from the patient and collateral history from a close relative or carer is paramount in the assessment ofsuspected cognitive impairment/dementia.Attention should be paid to • Mode of onset (when, where noticed) • Course of progression (rate, fluctuation) • Pattern of cognitive impairment (disorientation, poor short term memory, repetitive) • Presence of non-cognitive symptoms (behavioural disturbance, hallucinations, delusions, wandering, hoarding, anxiety, aggression, shouting, sexual disinhibition) • Review of medications that can potentially impair cognitive function • Presence of signs/symptoms of depression and anxietyA detailed physical examination should be performed, in particular, looking for focal neurology, motor features ofparkinsonism, signs indicative of vascular disease and hypothyroidism.The presence of co morbid depression should be considered and assessed routinely.Clinical phenotypes for different dementia syndromesDementia of Alzheimer’s type (DAT) (50 to 60%)DAT represents the commonest dementia syndrome. The average survival period after diagnosis is 8 to 10 years.Common symptoms in early disease include • Memory problems e.g. poor short term memory, disorientation, repetition, difficulty with new memory learning • Progressive deterioration in the ability to perform basic ADLs • Behaviour changes, mainly apathy and social withdrawal, but also behavioural disturbancesVascular dementia (VaD) (15 to 20%) • In some cases there may be a direct chronological relationship between discrete significant cerebrovascular events and the onset of cognitive impairment. • Patients may present with signs of stroke or other vascular problems e.g. ischaemic heart disease or hypertension. • Onset may be abrupt, with periods of sudden decline followed by relative stability. • Physical problems such as urinary incontinence, decreased mobility and balance problems are more commonly seen in people with vascular dementia (VaD) than in people with Alzheimer’s disease.Hachinski Ischaemic ScoreThe Hachinski Ischaemic Score (HIS) represents a brief clinical tool helpful in the “bedside” differentiation thecommonest dementia types, DAT and VaD. It’s utility has been validated by meta-analysis in pathologically verifiedpatients with dementia. A cut-off score ≤ 4 for DAT and ≥ 7 for VaD has a sensitivity of 89% and a specificity of 89%(Moroney 1997). It is not useful in determinations between mixed dementia and other dementia types. Item No. Description Value 1 Abrupt onset 2 2 Stepwise deterioration 1 3 Fluctuating course 2 4 Nocturnal confusion 1 5 Preservation of personality 1 6 Depression 1 7 Somatic complaints 1 8 Emotional incontinence 1 9 History of hypertension 1 10 History of stroke 2 11 Associated atherosclerosis 1SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 4/13
  • 5. 12 Focal neurological symptoms 2 13 Focal neurological signs 2HIS items distinguishing VaD from DAT were stepwise deterioration (odds ratio (OR), 6.06), fluctuating course (OR,7.60), hypertension (OR, 4.30), history of stroke (OR, 4.30) and focal neurological symptoms (OR, 4.40).Dementia with Lewy bodies (DLB) (5 to 10%)Characteristic features of DLB include: • Fluctuation of awareness from day-to-day. • Signs of parkinsonism such as tremor, rigidity and slowness of movement or poverty of expression. • Visual hallucinations or delusions occur frequently. • Falls are also common.DLB has a similar pathological basis to Parkinson’s disease dementia and both are associated with progressive cognitivedecline and parkinsonism. Approximately three quarters of people with Parkinson’s disease develop dementia after 10years.Fronto-temporal dementia (FTD) (5 to 10%)FTD is uncommon by comparison to DAT or VaD but represents a significant proportion of people who present withdementia under the age of 65. Changes in behaviour early in disease include disinhibition, lack of judgement, loss ofsocial awareness and loss of insight and are much more common than memory problems. Disturbance of mood, speechand continence are frequent. A positive family history of a similar disorder is not uncommon.Mixed dementias (20 to 30%)Mixtures of two or more of the active dementias can be found in the same person with oneor other phenotype usually dominating. Studies suggest that the interaction between vascular disease and the corefeatures of Alzheimer’s disease is extremely complex and that rigid boundaries between subtypes of dementia may beunduly artificial. Response to treatment or side effects from treatment in people with mixed dementia may be differentfrom those in people with a specific diagnosis.Diagnosis of deliriumA short section is included here with regard to the diagnosis of delirium due to the importance of excluding deliriumwhen assessing a person with cognitive problems. Please refer to the reference documentSVUH_MedEl_DeliriumReferencedoc_2008 for more complete information.Delirium is more common in the older person, with multiple medical co morbidities and underlying dementia. Delirium isdefined as disturbance of consciousness accompanied by change in cognition that is not better accounted for by a pre-existing dementia.Assessment must include a detailed history, physical examination and performance of appropriate investigations. Thesemay include blood tests, radiological investigations, urine analysis, electrocardiograph (ECG) and lumbar puncture ifcentral nervous system infection is suspected. Delirium is associated with negative outcomes including higher rates ofdeath, poorer function and lower MMSE test sores 2 years after discharge from hospital (Francis 1992).Evidence base for investigationsIt must be stressed that formal neuropsychological assessment remains the gold standard in defining thenature and extent of cognitive deficits. Local access to formal neuropsychological assessment is byreferral to the Old Age Psychiatry service.Cognition screening tools • The Mini-Mental State Examination (MMSE) was developed as a screening instrument for dementia and is widely used. The sensitivity of the MMSE ranges from 71% to 90% and specificity from 56% to 96% in primarySVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 5/13
  • 6. care depending on the age of the patient, educational level and cut-off score employed (Boustani2003). The brevity of the MMSE (30 points test) results in a superficial assessment of memory, language, and visuo- perceptual function. Processing speed and executive function are not tested. Evidence from a systematic review has shown that the MMSE is suitable for the detection of dementia in individuals with suspected cognitive impairment. Potential limitations include association with level of education and sensitivity to depression. It may also be misleading in individuals with either high or low premorbid ability and with certain types of dementia (especially VaD, DLB and FTD). • The clock-drawing test is a simple and useful tool for assessing praxis and executive function (Sunderland 1989). It may be used in combination with the MMSE. It consists of asking the patient to draw a clock face, complete with numbers and filling in the time using the long and short hands at a specified time. A number of different scoring systems exist for this test (Brodaty 1997). • The Addenbrooke’s Cognitive Examination-Revised (ACE-R) examines cognitive function more comprehensively. It also incorporates the MMSE. It is a 100-point test battery assessing six cognitive domains, including attention, orientation, memory, verbal fluency, language and visuo-spatial ability. The sensitivity of the ACE-R with a cut-off score of 88 is 94% with a specificity of 89%. When a cut-off score of 82 is used the sensitivity is 84% with a specificity of 100%. (Mioshi 2006).A benefit of these and similar tools is that they can be administered in a short period of time by a clinician, specialistnurse or occupational therapist.Blood testsBlood tests are done to exclude a potential reversible or modifying cause of dementia and also to help exclude commonmisdiagnoses including delirium. The investigations described below do not reflect an exhaustive list: • Routine haematology • Biochemistry tests (electrolytes, calcium, glucose, renal and liver function) • Thyroid function tests • Vitamin B12 and folate levels • Consider syphilis serology, genetic testing for Huntington’s disease, and H.I.V. serology as appropriate to the clinical setting.Brain imagingStructural imaging is used to exclude other cerebral pathologies (e.g. space-occupying lesions, normal pressurehydrocephalus) and to help establish the dementia type. However, sensitivity and specificity of structural imaging canvary and a systematic review found most had poor sensitivity and low specificity (Gifford 2000). MRI is preferred toassist with early diagnosis and to detect subcortical vascular changes. MRI may be used to quantify global corticalvolumetric loss and to determine if there is disproportionate regional atrophy in the medial temporal lobe andhippocampus areas. CT scanning could also be used.Functional imaging where available such as single-photon emission computed tomography (SPECT) or fluoro-deoxy-glucose positron emission tomography (FDG-PET) may be useful in differentiating between AD, VaD and FTD (Dougall2004, Mosconi 2005). Dopaminergic iodine-radio labelled (FP-CIT) SPECT may be used to aid in diagnosis of DLB(OBrien 2004).Other investigations • Electrocardiograph (ECG) should be performed, looking for conduction delays if use of acetylcholinesterase inhibitors (AChEI) is being considered. • Cerebrospinal fluid (CSF) is not routinely examined unless Creutzfeldt-Jakob Disease (CJD) or other forms of rapidly progressive dementia are suspected. Protein 14-3-3 is associated with rapid neuronal loss and has high predictive value (>90% sensitivity and specificity) for CJD (Hsich 1996). • Electroencephalograph (EEG) is not used routinely in the diagnosis of dementia as the resting EEG often describes non-specific diffuse abnormalities. EEG is useful if disorders such as delirium (gross-slowing), fronto- temporal dementia (normal) or CJD (triphasic spikes) are suspected. • Urinalysis should be performed to outrule possible delirium secondary to infection.SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 6/13
  • 7. Disclosure of diagnosis and supports availableHealthcare professionals should • Ask assessed patients if they wish to be informed of a diagnosis of dementia and with whom the diagnosis should be shared. • Seek formal permission where possible to disclose diagnosis to carers. • Be aware that many patients with dementia can understand their diagnosis, receive information and be involved in decision making. • Be aware that some patients with dementia may not wish to know their diagnosis.A healthcare professional skilled in communication or counselling should give the diagnosis of dementia. Disclosure topatients may be considered unhelpful if cognitive deficits limit their ability to understand the meaning and implications oftheir diagnosis. Diagnosis disclosure can lead to mixed reactions, such as shock, distress, ambivalence or confirmation ofexisting suspicions. Where diagnosis is not disclosed there should be a clear record of the reasons.It is important to explain to patients and family that in many cases, the definitive diagnosis of the subtype of dementiamay not be possible until or unless post-mortem examination is performed. The sensitivity and specificity of the variouscognitive tests, neuro-imaging and diagnostic criteria can be discussed if necessary.The patient and family should be given information on • Course and prognosis of cognitive impairment/dementia • Interventions available • Services and social supports available in the community • Sources of financial and legal advice and advocacy • Medico-legal issues including drivingInformation given to patient and family should be recorded in the medical notes.Where possible, it is always best to provide care for patients with dementia in their own home environment. Encouragethe patient and family to avail of local social supports such as public health nurse visits, attendance at a local day centre,delivered meals, personal alarm monitoring service and respite services. The issue of extended nursing care should bebrought up as appropriate during the discussion on course and prognosis of dementia. Patients with mild cognitive andfamily should be advised to seek legal advice with regard to matters such as enduring power of attorney and making ofwills.Driving & dementiaDeliberations about driving should be made taking the level of cognitive function into consideration. This assessmentshould include a full history (including a collateral driving history), multidisciplinary assessment (cognitive testingincluding tests for executive dysfunction, visuo-spatial and perceptual deficits) and possibly an appropriate on-road test.A physical examination for focal weakness or visual field deficits as well as a history of seizures should be documented inthe clinical notes.If family members express serious concerns over incidences while driving, the cessation of driving should be advised.Where an incident is associated with an acute illness or episode of decompensation, it is reasonable to follow the aboveplan of assessment once the episode has resolved.Cautious but reasonable general advice could include suggesting that patients with dementia who have not experiencedany problems driving might confine their driving to their own locality and only during day light hours.Social factors that need to be taken into consideration with regard to driving include the availability of an alternativeform of transportation and the social support network of the patient. It is often necessary to stress the importance ofdriving cessation and emphasize the advice with a letter to the patient and the general practitioner.Evidence suggests that in the first 2 years of dementia, the risk of driving approximates that of the general population(Drachmann 1993). A case controlled study of crashes and dementia showed no increase in crash rates for drivers withdementia (Trobe 1996). Likely causes for these findings include lower mileage and restriction of driving by patient,SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 7/13
  • 8. family and doctor. A study showed that drivers with dementia who drive accompanied have fewer crashes than thosewho drive alone. (Bedard 1996).These findings are important as many doctors assume that dementia is an absolute contraindication to driving. Dementiais a heterogeneous condition and its effects on the driving task are complex. For example, it was found that 10% ofpatients had deteriorations in driving skills in the early stages of dementia (ONeill 1992). Consequently thedetermination on driving ability in the presence of dementia should include the above systematic assessment or similarassessment method (ONeill, Oxford textbook of Geriatric Medicine).Therapeutic InterventionsNo curative therapies for any of the dementia syndromes currently exist. Interventions may be non-pharmacological orpharmacological. The principal aims of interventions are • Promotion of independence and maintenance of function. • Management of non-cognitive symptoms and challenging behaviour. • Reduction of co morbid emotional disorders.Non-pharmacological interventionsThe onset of non-cognitive symptoms or challenging behaviour in patients with dementia, should prompt patient re-assessment to attempt to identify aggravating factors, including • Physical health • Depression • Possible undetected pain or discomfort • Side effects of medication • Individual biography • Psychosocial factors • Environmental factorsDepending on availability, consider options including aromatherapy, therapeutic use of music and/or dancing, animal-assisted therapy & massage.Pharmacological interventionsAcetylcholinesterase inhibitorsAlzheimers disease (DAT) is associated with loss of cholinergic neurones in certain parts of the brain. Donepezil(Aricept®) is a reversible inhibitor of acetylcholinesterase. Rivastigmine (Exelon®) is a reversible inhibitor ofacetylcholinesterase and butyrylcholinesterase. Galantamine (Reminyl®) is a reversible inhibitor of acetylcholinesteraseand also has nicotinic receptor agonist properties. The AChEI group of drugs reduce enzymatic breakdown ofacetylcholine thus increasing the concentration of acetylcholine released by intact cholinergic neurones, therebyfacilitating cholinergic neurotransmission.Acetylcholinesterase inhibitors (AChEI) donepezil, galantamine and rivastigmine are licensed for the symptomatictreatment of mild to moderately severe Alzheimer’s disease. The results of 10 randomized, double blind, placebocontrolled trials demonstrated that 6 months treatment with the above AChEIs at the recommended dose for people withmild, moderate or severe dementia due to Alzheimer’s disease produced improvements in cognitive function, on average-2.7 points (95%CI -3.0 to -2.3, p<0.00001), in the 70 point Alzheimers disease Assessment (ADAS-Cog) Scale (Birks2006). Benefits of treatment were also seen on measures of activities of daily living and behaviour. None of thesetreatment effects were large.Only rivastigmine is currently licensed for the symptomatic treatment of patients with dementia in Parkinsons disease.Rivastigmine appeared to have clinically meaningful benefit in approximately 15% of patients with dementia inParkinsons disease (Maidment 2006). Tolerability of rivastigmine in particular nausea, vomiting and tremor areproblematic. No other drug is currently licensed for VaD, DLB, FTD or other dementias (subcortical or mixed dementias).Evidence of efficacy of donepezil for people with mild or moderate vascular cognitive impairment is limited. Commonlyhowever, the AChEIs and memantine are currently prescribed in dementia other than Alzheimer’s type, at clinicaldiscretion without licence.SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 8/13
  • 9. There is no evidence to support the use of AChEI for patients with MCI. The putative benefits are minor, short lived andassociated with significant side effects.AChEIs should be offered to patients with moderate DAT, in general with MMSE scores of 10 to 20. AChEI treatmentshould also be considered when there is a requirement to modulate the behavioural symptoms of dementia. Healthcareprofessionals should not rely on the MMSE score in patients who: • Score greater than 20, but who have moderate dementia as judged by significant impairments in functional ability and personal and social function compared with premorbid ability • Score less than 10 because of a low premorbid attainment or ability or linguistic difficulties, but who have moderate dementia as judged by an assessment tool sensitive to their level of competence • Are not fluent in the language in which the MMSE is given • Have learning disabilitiesDepending on the type of AChEI, it may be available in tablet, liquid or topical patch form. A specialist in dementia careshould start treatment. The specialist should • Seek carers’ views on the condition of the person with dementia at baseline • Choose an AChEI keeping in mind the adverse-event profile, concordance issues, co morbidities, possible drug interactions and dosing profiles • Review MMSE score and global, functional and behavioural assessment every 6 months • Seek carers’ views on the condition of the person with dementia at follow-up • Continue treatment if the MMSE score remains at or above 10 points and global, functional and behavioural condition indicates worthwhile effect.MemantineL-glutamate is the main excitatory neurotransmitter in the central nervous system (CNS), implicated in neuraltransmission, learning, memory and neuronal plasticity. Enhancement of the excitatory action of L-glutamate may play arole in the pathogenesis of DAT. Memantine (Ebixa®) is a low-affinity N-methyl-D-aspartate (NMDA)-receptor antagonistthat may prevent excitatory amino acid neurotoxicity without interfering with the actions of glutamate necessary forlearning and memory.Memantine is licensed for moderate to severe DAT, were the evidence supports a small beneficial effect at six months oftreatment. This small beneficial effect was not detected in patients with VaD (McShane 2006).AChEI and memantine may be withdrawn if/when the treatment is deemed to be no longer beneficial. Treatmentsshould only be withdrawn during an unplanned or emergency hospital admission if they are directly implicated in theaetiology of the patient’s acute deterioration, as the treatment withdrawal may provoke deterioration in behavioural orcognitive symptoms.Antipsychotic medicationAntipsychotic medication should be prescribed for severe non-cognitive symptoms (psychosis and/or agitated behaviourcausing significant distress) only if there is severe distress or an immediate risk of harm to the person with dementia orothers. The treatment should be commenced only if • Risks and benefits have been fully discussed; assess cerebrovascular risk factors and discuss possible increased risk of stroke/transient ischaemic attack and possible adverse effects on cognition • Changes in cognition are regularly assessed and recorded; consider alternative medication if necessary • Target symptoms have been identified, quantified and documented, and changes are regularly assessed and recorded • Co morbid conditions, such as depression, have been considered • The drug dose is started low and titrated upwards • Treatment is time limited and regularly reviewed (every 3 months or according to clinical need).Treatment with haloperidol, pimozide, and ziprasidone is contraindicated in the following circumstances (Neurolepticsand Cardiac Side Effects IMB publication) • Clinically significant cardiac disorders (e.g. recent acute myocardial infarction, uncompensated heart failure, arrhythmias treated with class IA and III antiarrhythmic medicinal products) • QTc interval prolongation on ECGSVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 9/13
  • 10. • History of ventricular arrhythmia or Torsades de pointes, • Uncorrected hypokalaemia • Patients taking other QT prolonging drugs.These substances should be used with caution in patients with cardiovascular disease or a family history of QTprolongation.It is recommended that patients undergo a baseline ECG prior to commencement of treatment and that the need for on-going ECG monitoring is assessed on an individual patient basis. Whilst on therapy, the dose of neuroleptic should bereduced if the QT is prolonged and should be discontinued if QTc is > 500ms. Periodic electrolyte monitoring isrecommended during therapy and the concomitant use of other neuroleptic medicines should be avoided.In DLB, monitor particularly for neuroleptic sensitivity reactions (development or worsening of extra pyramidal featuresor acute, severe physical deterioration). Neuroleptic malignant syndrome (NMS) can develop in 0.1% to 2.5% of allpatients treated with neuroleptics (Kornhuber 1994). Mortality in NMS ranges from 2.0% to 16% with differenttreatment modalities (Reulbach 2007).Future de novo therapiesTrials are currently underway for possible future therapies in treatment and prevention of Alzheimers disease especiallyin the field of immunotherapy and vaccines. A common target is the beta-amyloid protein for which antibodies andvaccines are being tested. Etanercept, an anti-tumour necrosis factor alpha protein is also being studied as a possible denovo therapy. Results from these trials are awaited.Useful information sources/websites Organisation Contact details St. Vincent’s University Hospital, Dept of Ms. Lorraine Murray, Senior Administrator Geriatric Medicine T: 01- 2094549 F: 01-2094609 St. Vincent’s University Hospital Carew T: 01- 2094122 F: 01-2094026 House Day Hospital The Alzheimer Society of Ireland T: 1800 341341 http://www.alzheimer.ie The Carers Association T: 057-9322920 http://www.carersireland.com Dementia Services Information & T: 01-4162035 Fax: 01-4163482 http://www.dementia.ie Development Centre The Mercers Institute for Research on http://www.stjames.ie Ageing Transport and Mobility Consultants Ireland Mr. Tony Regan Tel: 0404-43854 email: tonyregan@ireland.comSVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 10/13
  • 11. ReferencesBedard M, Molloy M, Lever J. (1996). Should demented patients drive alone? Journal of the American Geriatrics Society.44, S9.Birks J. Cholinesterase Inhibitors for A;zheimers Disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art.No.: CD005593. DOI: 10.1002/14651858.CD005593.Boustani M, MD, MPH; Britt Peterson, MD, MPH; Laura Hanson, MD, MPH; Russell Harris, MD, MPH; and Kathleen N.Lohr, PhD Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services TaskForce Ann Intern Med. 2003;138:927-937.Brodaty H, Moore CM. The Clock Drawing Test for dementia of the Alzheimers type: A comparison of three scoringmethods in a memory disorders clinic. Int J Geriatr Psychiatry. 1997 Jun;12(6):619-27Dougall, N.J., Bruggink, S. & Ebmeier, K.P. (2004) Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. American Journal of Geriatric Psychiatry, 12, 554–570.Drachmann DA, Sweaver JM. (1993) Driving and Alzheimers disease: the risk of crashes. Neurology, 43, 2448-56Francis J, Kapoor WM. Prognosis after hospital discharge of older medical patients with delirium. Journal of the AmericanGeriatrics Society 1992 40;601-6Gifford, D.R., Holloway, R.G. & Vickrey, B.G. (2000) Systematic review of clinical prediction rules for neuroimaging in theevaluation of dementia. Archives of Internal Medicine, 160, 2855–2862.Gold, G., Bouras, C., Canuto, A., et al. (2002) Clinicopathological validation study of four sets of clinical criteria forvascular dementia. The American Journal of Psychiatry, 159, 82–87.Hofman, A., Ott, A., Breteler, M.M., et al. (1997) Atherosclerosis, apolipoprotein E and prevalence of dementia andAlzheimer’s disease in the Rotterdam Study. The Lancet, 349, 151–154.Hsich, G., Kenney, K., Gibbs, C.J, et al. (1996) The 14-3-3 brain protein in cerebrospinal fluid as a marker fortransmissible spongiform encephalopathies. New England Journal of Medicine, 335, 924–930.http://www.alzheimer.ieJayadev S, Steinbart EJ, Chi YY, Kukull WA, Schellenberg GD, Bird TD. Conjugal Alzheimer disease: risk in children whenboth parents have Alzheimer disease. Arch Neurol. 2008 Mar;65(3):373-8.Knopman, D.S., DeKosky, S.T., Cummings, J.L., et al. (2001) Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56,1143–1153.Kornhuber J, Weller M: Neuroleptic malignant syndrome. Curr Opin Neurol 1994, 7:353-357.Lai F, Williams RS. Arch Neurol. 1989 Aug;46(8):849-53. A prospective study of Alzheimer disease in Down syndrome.Litvan, I., Bhatia, K.P., Burn, D.J., et al. (2003) Movement Disorders Society Scientific Issues Committee report: SICTask Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Movement Disorders, 18, 467–486.Lobo, A., Launer, L.J., Fratiglioni, L., et al. (2000) Prevalence of dementia and major subtypes in Europe: a collaborativestudy of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology, 54, S4–S9.Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database ofSystematic Reviews 2006, Issue 1. Art. No.: CD004747. DOI: 10.1002/14651858.CD004747.pub2.SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 11/13
  • 12. McKeith, I.G., Ballard, C.G., Perry, R.H., et al. (2000) Prospective validation of consensus criteria for the diagnosis ofdementia with Lewy bodies. Neurology, 54, 1050–1058McKeith, I.G., Dickson, D.W., Lowe, J., et al. (2005) Diagnosis and management of dementia with Lewy bodies: thirdreport of the DLB Consortium. Neurology, 65, 1863–1872.McKeith, I.G., Galasko, D., Kosaka, K., et al. (1996) Consensus guidelines for the clinical and pathologic diagnosis ofdementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology, 47, 1113–1124.McKhann, G., Drachman, D., Folstein, M., et al. (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’sDisease. Neurology, 34, 939–944.McKhann, G.M., Albert, M.S., Grossman, M., et al. (2001) Clinical and pathological diagnosis of frontotemporal dementia:report of the Work Group on Frontotemporal Dementia and Pick’s Disease. Archives of Neurology, 58, 1803–1809.McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006,Issue 2. Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.pub5.Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. Int J Geriatr Psychiatry. 2006 Nov;21(11):1078-85. TheAddenbrookes Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening.Moroney, J.T., Meta-analysis of the Hachinski Ischaemic Score in pathologically verified dementias. Neurology, 49, 1096– 1105.Mosconi, L. (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studiesin MCI and AD. European Journal of Nuclear Medicine and Molecular Imaging, 32, 486–510.Neary, D., Snowden, J.S., Gustafson, L., et al. (1998) Frontotemporal lobar degeneration: a consensus on clinicaldiagnostic criteria. Neurology, 51, 1546–1554.Neuroleptics and Cardiac Side Effects. Irish Medicines Board Notice Information:Human Medicines Publication-31st May2007O’Brien, J.T., Colloby, S., Fenwick, J., et al. (2004) Dopamine transporter loss visualized with FP-CIT SPECT in thedifferential diagnosis of dementia with Lewy bodies. Archives of Neurology, 61, 919–925. ONeill D. (1992) Physicians,elderly drivers and dementia. Lancet 1992 339, 41-3.ONeill D. Driving and Mobility. Oxford textbook of Geriatric Medicine 2nd Edition. 1157-1164.Peters, R., Peters, J., Warner, J., Beckett, N., Bulpitt, C. (2008) Alcohol, dementia and cognitive decline in the elderly: asystematic review. Age and Ageing 2008; 37:505-12.Reulbach U, Dütsch C, Biermann T, Sperling W, Thuerauf N, Kornhuber J, Bleich S. Managing an effective treatment forneuroleptic malignant syndrome. Crit Care. 2007;11(1):R4.Rocca, W.A., Hofman, A., Brayne, C., et al. (1991) Frequency and distribution of Alzheimer’s disease in Europe: acollaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Annals of Neurology,30, 381–390.Roman, G.C., Tatemichi, T.K., Erkinjuntti, T., et al. (1993) Vascular dementia: diagnostic criteria for research studies.Report of the NINDS-AIREN international Workshop. Neurology, 43, 250–260.Saunders, P.A., Copeland, J.R., Dewey, M.E., et al. (1991) Heavy drinking as a risk factor for depression and dementia inelderly men. Findings from the Liverpool longitudinal community study. The British Journal of Psychiatry, 159,213–216.Strittmatter, W.J., Saunders, A.M., Schmechel, D., et al. (1993) Apolipoprotein E: high-avidity binding to beta-amyloidand increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy ofSciences of the United States of America, 90, 1977–1981.SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 12/13
  • 13. Trobe JD, Waller PF, Cook-Flannagan CA, Teshima SM, Bieliuskas LA (1996) Crashes and violations among drivers withAlzheimers disease. Archives of Neurology, 53, 411-16.Valenzuela, M.J. & Sachdev, P. (2005) Brain reserve and dementia: a systematic review. Psychological Medicine, 35, 1–14.Verghese, J., Lipton, R.B., Katz, M.J., et al. (2003) Leisure activities and the risk of dementia in the elderly. The NewEngland Journal of Medicine, 348, 2508–2516.White, N., Scott, A., Woods, R.T., et al. (2002) The limited utility of the mini mental state examination in screeningpeople over the age of 75 years for dementia in primary care. The British Journal of General Practice, 52, 1002–1003.Wilson, R.S., Mendes De Leon, C.F., Barnes, L.L., et al. (2002) Participation in cognitively stimulating activities and riskof incident Alzheimer disease. The Journal of the American Medical Association, 287, 742–748.SVUH_MedEl_DementiaReferencedoc_DraftGH2_2008 13/13